Cedars-Sinai Medical Center

Cedars-Sinai Medical Center operates as a non-profit, tax-exempt hospital and academic medical center headquartered in West Hollywood, California, functioning as a prime recipient for federal biomedical research grants and a prime awardee on federal research contracts. The medical center holds a single-award $500 million indefinite delivery contract with the National Heart, Lung, and Blood Institute for the Trans-Omics for Precision Medicine (TopMed) Centralized Omics Resource, with task orders through September 2033 for complex data analysis, integration, and management of large-scale genomic and health datasets supporting precision medicine initiatives.

Cedars-Sinai's federal portfolio concentrates heavily in health research and clinical services. The organization serves as prime recipient on 840 awards spanning grant work, research contracts, and contract IDVs (74% of recent activity), with 297 sub-awards representing 26%. Over the past five years, federal award volume has grown from 73 in 2022 to 148 in 2024, before moderating to 127 in 2025 and 52 in 2026 (the latter a partial-year count). The combined potential value across all awards stands at approximately $1.02 billion, though total obligations across all awards reach $2.19 billion, indicating substantial reobligations and task order activity against standing IDVs and contracts. The medical center's most recent award, dated October 22, 2026, is a $52,200 Cardiac Suite Quantitative PET software licensing purchase order from the Veterans Integrated Service Network 22.

Customer concentration sits overwhelmingly with the National Institutes of Health (NIH) and its component institutes. The Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute leads by both award count and dollar value (166 awards, $1.01 billion combined potential value). The National Cancer Institute ranks second in award count (164 awards, $6.7 million combined potential value), followed by the National Institute of Diabetes and Digestive and Kidney Diseases (82 awards), the National Institute of Allergy and Infectious Diseases (78 awards), and the National Institute on Aging (59 awards). These five entities account for 56% of awards by count and 99% of combined potential value. Within the NIH, Cedars-Sinai operates across research grant programs including the R01, R21, R35, K01, K99/R00, P50, SCORE, and cooperative agreement mechanisms, alongside project grants spanning basic science, translational, and clinical research. Named federal agencies with significant activity beyond NIH include the Defense Health Agency (which funds Military Medical Research and Development initiatives and houses DHA grants across oncology, neuroscience, cardiovascular disease, and translational medicine), the Veterans Administration (Veterans Integrated Service Network regional offices), the National Science Foundation, and the Centers for Disease Control and Prevention.

Cedars-Sinai's capability footprint reflects its identity as an academic medical center: biomedical research spanning cancer biology, cardiology, neuroscience, immunology, aging research, and translational medicine. Representative recent prime grants include a $2.59 million National Institute on Aging award (September 2025) investigating hypothalamic pathways in age-related homeostatic dysregulation; a $6.15 million Defense Health Agency grant (August 2025) for therapeutic development of noncoding RNA drug TY1 for scleroderma; a $3.48 million National Institute of Environmental Health Sciences award (September 2025) developing AI and machine learning methods for large-scale epidemiological studies using patient-generated medication adherence reports; and a $2.4 million National Institute of Dental and Craniofacial Research grant (August 2025) to bionengineer vascularized oral mucosal grafts from induced pluripotent stem cells. Prime contract work has been minimal in scale: two small Veterans Administration purchase orders for data migration ($13,250) and Cardiac Suite software licensing ($52,200) in 2025–2026. The organization's research scope spans Aims structured around mechanistic investigations, biomarker discovery, therapeutic development, clinical trial design, and patient-centered outcomes measurement across disease domains including cancer, heart disease, diabetes, kidney disease, neurodegenerative conditions, and infectious disease.

Teaming posture reflects Cedars-Sinai's anchor role in the Los Angeles research ecosystem. As prime recipient on 74% of awards, the organization builds research teams composed of internal investigators and departmental faculty. On grant sub-awards (297 total, representing 26% of activity), Cedars-Sinai frequently partners with peer academic medical centers and universities, frequently contributing specific expertise (imaging, biostatistics, cell biology, clinical trial enrollment, or specimen banking). Named sub-awardee relationships include collaborations with the University of Pennsylvania (multiple HLA immunogenetics and biomarker studies), Columbia University (neurophysiology and cardiac allograft research), UCLA (brain imaging, therapeutic development, training programs), UC San Francisco (oral mucosa bioengineering), UC Davis (human neurophysiology, epidemiology), Yale University (immune dysfunction genetics), the California Institute of Technology (neuronal recording and imaging), Mayo Clinic (aging research, clinical trial infrastructure), Fred Hutchinson Cancer Center (oncology biomarkers and lifestyle interventions), and the University of Colorado (microgravity and stem cell manufacturing). On the rare contract sub-award side, Cedars-Sinai has sub-contracted to the University of Colorado for NASA-related microgravity research in iPSC manufacturing.

Service Contract Inventory (SCI) data covers federal service contracts above the $150,000 reporting threshold and excludes goods, micro-purchases, and classified work. The source reports 6 SCI records (3 as prime, 3 as named subcontractor) spanning FY2022–FY2024, with zero invoiced revenue reported across all fiscal years and minimal FTE presence (0.4 FTEs in FY2022, declining to 0.0 by FY2023–FY2024). SCI is a partial snapshot: the dataset does not capture contract invoicing, grant revenue, or non-federal activities, and does not reflect the substantial scale of research operations visible in the grant and IDC footprint.

Cedars-Sinai operates with named subsidiary Pasadena Hospital Association, LTD., a hospital and non-profit organization. The medical center's headquarters address is 8700 Beverly Blvd, West Hollywood, CA 90048. A recompete cliff of 118 awards (combined potential value $3.6 million) faces ultimate completion in the next 24 months, representing a modest but recurrent stream of renewal and competitive opportunity.